Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
Coherus Biosciences Inc (NASDAQ: CHRS) closed the day trading at $0.76 down -0.91% from the previous closing price of $0.77. In other words, the price has decreased by -$0.91 from its previous closing price. On the day, 1.6 million shares were traded.
Ratios:
For a better understanding of CHRS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.07 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 176.46. For the most recent quarter (mrq), Quick Ratio is recorded 1.20 and its Current Ratio is at 1.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.
On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $2.43, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is -18.86%, while the 200-Day Moving Average is calculated to be -32.86%.
Shares Statistics:
A total of 115.91M shares are outstanding, with a floating share count of 111.33M. Insiders hold about 3.97% of the company’s shares, while institutions hold 50.86% stake in the company.
